



Substitute for form 1449A/PTO

PTO/SB/08a (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
a collection of information unless it contains a valid OMB control number.

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

EXAMINER: Dr. K.C. Srivastava

(Use as many sheets as necessary)

Sheet 1 of 1

Digitized by srujanika@gmail.com

Sheet 1 of 1

**Complete if Known**

Application Number	10/687,706
Filing Date	10/20/2003
First Named Inventor	LOSCALZO, et al.
Art Unit	4661 1657
Examiner Name	To Be Assigned
Attorney Docket Number	102258.170US2

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Line

Examiner  
Signature

/Kailash Srivastava/

Date Considered

09/04/2008

\*EXAMINER: Initial if response considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document. 6 Appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/687,706
				Filing Date	10/20/2003
				First Named Inventor	LOSCALZO, et al.
				Art Unit	1654 1657
				Examiner Name	To Be Assigned
				Attorney Docket Number	102258.170US2
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
/K.S./	AA	FRANCIOSA, Joseph A., "African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology," Journal of Cardiac Failure, Vol. 8, No. 3, 2002, pp. 128-135				
	AB	YANCY, Clyde W., et al., "Race and the Response to Adrenergic Blockage with Carvedilol in Patients with Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1358-1365				
	AC	YANCY, Clyde W., "Heart Failure in African Americans: A Cardiovascular Enigma," Journal of Cardiac Failure, Vol. 6, No. 3, 2000, pp. 183-186				
	AD	EXNER, Derek V., et al., "Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1351-1357				
	AE	PACKER, Milton, et al., "Effect of Carvedilol on Survival in Severe Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1651-1658				
	AF	"A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1659-1667				
	AG	BRAUNWALD, Eugene, "Expanding Indications for Beta-Blockers in Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1711-1712				
	AH	SCHWARTZ, Robert S., "Racial Profiling in Medical Research," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1392-1393				
	AI	LEVINE, T. Barry, "Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy," American Journal of Hypertension, Ltd., 1998; 11:1041-1047				
/K.S./	AJ	ABSTRACTS - Heart Failure 179A, JACC, February 1999				

Examiner Signature	/Kailash Srivastava/	Date Considered	09/04/2008
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/687,706
EXAMINER: Dr. K.C. Srivastava			Filing Date	10/20/2003
(Use as many sheets as necessary)			First Named Inventor	LOSCALZO, et al.
Sheet	3	of	Attorney Docket Number	102258.170US2

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/K.S./	AK	KAHN, Jonathan, "How a Drug Becomes "Ethnic": Law, Commerce, and the Production of Racial Categories in Medicine," <i>Yale Journal of Health Policy, Law, and Ethics</i> IV:1 (2004), pp. 1-46	
/K.S./	AL	PARKER, John D., et al., "The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 280, No. 2, pp. 866-875	
/K.S./	AM	KALINOWSKI, Leszek, et al., "Race-Specific Differences in Endothelial Function - Predisposition of African Americans to Vascular Diseases," <i>Circulation</i> , June 1, 2004, pp. 2511-2517	

Examiner Signature	/Kailash Srivastava/	Date Considered	09/04/2008
-----------------------	----------------------	--------------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.